Table 3.

Prognostic factors for overall survival by univariate and multivariate analyses in pancreatic cancer (n = 105)

	Univariate analysis	Multivariate analysis
	HR (95% CI); P	HR (95% CI); P
Age (>65 yr)	1.00 (0.62–1.63); 0.97	NS
Sex (male)	0.84 (0.56–1.27); 0.41	NS
TNM stage (III–IV/I–II)	1.35 (0.74–2.48); 0.33	NS
Location of mass (head, uncinate/body, and tail)	1.28 (0.85–1.93); 0.23	NS
Tumor size (>20 mm)	1.26 (0.69–2.31); 0.45	NS
CEA (>10 ng/mL)	0.64 (0.42–0.99); 0.51	NS
CA19-9 (>37 U/mL)	1.75 (1.15-2.76); 0.04a	NS
EUF-FNA KRAS	0.85 (0.52–1.39); 0.52	NS
G12D KRAS	1.94 (1.12-3.36); <0.0001b	1.495 (1.325-1.753); 0.0010b
G12V KRAS	1.23 (0.80–1.90); 0.35	NS
G12R KRAS	0.43 (0.29–0.66); 0.02a	NS
ctDNA KRAS	0.540 (0.379–1.417); 0.3559	NS
G12D KRAS	1.579 (1.383–3.520); 0.0005b	1.417 (1.199–2.870); 0.0199a
G12V KRAS	0.993 (0.393–2.508); 0.9881	NS
G12R KRAS	0.296 (0.149–0.589); 0.5276	NS

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; NS, no significance.

^aP<0.05; ^bP<0.01.